Trials / Completed
CompletedNCT03247816
Feraccru® Real World Effectiveness Study in Hospital Practice ( FRESH )
Feraccru® Real World Effectiveness Study in Hospital Practice (FRESH): A Real World Study to Describe the Outcomes Associated With the Use of Ferric Maltol (Feraccru) for the Management of Iron Deficiency Anaemia in Patients With Inflammatory Bowel Disease in the UK.
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 59 (actual)
- Sponsor
- Shield Therapeutics · Industry
- Sex
- All
- Age
- 18 Years – 99 Years
- Healthy volunteers
- Not accepted
Summary
The aim of the study is to understand the early experiences of Feraccru® in patients with inflammatory bowel disease (IBD) and iron deficiency anaemia (IDA) in the UK, including treatment effectiveness, patterns of use and tolerability.
Detailed description
The aim of the study is to understand the early experiences of Feraccru® in patients with inflammatory bowel disease (IBD) and iron deficiency anaemia (IDA) in the UK, including treatment effectiveness, patterns of use and tolerability. By describing the characteristics of patients treated with Feraccru® and their outcomes, this study will provide the medical community with important information to support treatment decisions for their patients. This will ultimately support improvements to patient care, including the long-term outcomes of patients with IBD and IDA
Conditions
Timeline
- Start date
- 2017-08-14
- Primary completion
- 2018-03-01
- Completion
- 2018-10-01
- First posted
- 2017-08-14
- Last updated
- 2020-10-23
- Results posted
- 2020-09-25
Locations
1 site across 1 country: United Kingdom
Source: ClinicalTrials.gov record NCT03247816. Inclusion in this directory is not an endorsement.